Search   
MSDS  : 5H-Dibenz(b,f)azepine, 5-(3-(dimethylamino)propyl)-10,11-dihydro-, monohydrochloride
CAS  : 113-52-0
SYNONYMS  : * Antideprin hydrochloride * Chimoreptin * Chrytemin * Co cap imipramine 25 * Deprinol * 5H-Dibenz(b,f)azepine, 10,11-dihydro-5-(3-(dimethylamino)propyl)-, hydrochloride * 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-, monohydrochloride * 5-(3-Dimethylaminopropyl)-10,11-dihydro-5H-dibenz(b,f)azepine hydrochloride * N-(gamma-Dimethylaminopropyl)iminodibenzyl hydrochloride * N-(3-Dimethylaminopropyl)iminodibenzyl hydrochloride * N-(gamma-Dimetilaminopropil)-iminodibenzile cloridrato * Dynazina * Efuranol * Feinalmin * Fujisawa * G 22355 * IA-Pram * Imavate * Imidol * Imilanyle * Imipramine hydrochloride * Imipramine monohydrochloride * Iprogen * Janimine * Melipramine hydrochloride * NSC 114900 * Persamine * Pertofram * Presamine * Pryleugan * SK-Pramine hydrochloride * Teperine * Tofranil * Tofranile
*** CHEMICAL IDENTIFICATION ***

RTECS NUMBER : HO1925000
CHEMICAL NAME : 5H-Dibenz(b,f)azepine,
5-(3-(dimethylamino)propyl)-10,11-dihydro-,
monohydrochloride
CAS REGISTRY NUMBER : 113-52-0
LAST UPDATED : 199706
DATA ITEMS CITED : 41
MOLECULAR FORMULA : C19-H24-N2.Cl-H
MOLECULAR WEIGHT : 316.91
WISWESSER LINE NOTATION : T C676 BN&T&J B3N1&1 &GH
COMPOUND DESCRIPTOR : Drug
Mutagen
Reproductive Effector
Human
SYNONYMS/TRADE NAMES :
* Antideprin hydrochloride
* Chimoreptin
* Chrytemin
* Co cap imipramine 25
* Deprinol
* 5H-Dibenz(b,f)azepine, 10,11-dihydro-5-(3-(dimethylamino)propyl)-,
hydrochloride
* 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-,
monohydrochloride
* 5-(3-Dimethylaminopropyl)-10,11-dihydro-5H-dibenz(b,f)azepine
hydrochloride
* N-(gamma-Dimethylaminopropyl)iminodibenzyl hydrochloride
* N-(3-Dimethylaminopropyl)iminodibenzyl hydrochloride
* N-(gamma-Dimetilaminopropil)-iminodibenzile cloridrato
* Dynazina
* Efuranol
* Feinalmin
* Fujisawa
* G 22355
* IA-Pram
* Imavate
* Imidol
* Imilanyle
* Imipramine hydrochloride
* Imipramine monohydrochloride
* Iprogen
* Janimine
* Melipramine hydrochloride
* NSC 114900
* Persamine
* Pertofram
* Presamine
* Pryleugan
* SK-Pramine hydrochloride
* Teperine
* Tofranil
* Tofranile

*** HEALTH HAZARD DATA ***

** ACUTE TOXICITY DATA **

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Human - man
DOSE/DURATION : 2143 ug/kg/2D-I
TOXIC EFFECTS :
Behavioral - tremor
REFERENCE :
JCLPDE Journal of Clinical Psychiatry. (Physicians Postgraduate Press,
Inc., POB 240008, Memphis, TN 38124) V.39- 1978-
Volume(issue)/page/year: 44,225,1983

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Human - child
DOSE/DURATION : 25 mg/kg
TOXIC EFFECTS :
Behavioral - sleep
Behavioral - convulsions or effect on seizure threshold
Lungs, Thorax, or Respiration - dyspnea
REFERENCE :
JAMAAP JAMA, Journal of the American Medical Association. (AMA, 535 N.
Dearborn St., Chicago, IL 60610) V.1- 1883- Volume(issue)/page/year:
179,456,1962

TYPE OF TEST : LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Human - child
DOSE/DURATION : 15 mg/kg
TOXIC EFFECTS :
Sense Organs and Special Senses (Eye) - mydriasis (pupillary dilation)
Cardiac - other changes
Kidney, Ureter, Bladder - other changes
REFERENCE :
BMJOAE British Medical Journal. (British Medical Assoc., BMA House,
Tavistock Sq., London WC1H 9JR, UK) V.1- 1857- Volume(issue)/page/year:
1,261,1974

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Human - child
DOSE/DURATION : 27 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity)
Behavioral - muscle contraction or spasticity
Kidney, Ureter, Bladder - other changes
REFERENCE :
JAMAAP JAMA, Journal of the American Medical Association. (AMA, 535 N.
Dearborn St., Chicago, IL 60610) V.1- 1883- Volume(issue)/page/year:
230,1405,1974

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Human - woman
DOSE/DURATION : 70 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity)
Cardiac - pulse rate increase, without fall in BP
Vascular - BP lowering not characterized in autonomic section
REFERENCE :
AJEMEN American Journal of Emergency Medicine. (WB Saunders, Philadelphia,
PA) V.1- 1983- Volume(issue)/page/year: 12,456,1994

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Human - woman
DOSE/DURATION : 30 mg/kg
TOXIC EFFECTS :
Peripheral Nerve and Sensation - paresthesis
Behavioral - convulsions or effect on seizure threshold
REFERENCE :
BMJOAE British Medical Journal. (British Medical Assoc., BMA House,
Tavistock Sq., London WC1H 9JR, UK) V.1- 1857- Volume(issue)/page/year:
2,1458,1959

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Rodent - rat
DOSE/DURATION : 305 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E.
First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year:
18,185,1971

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intraperitoneal
SPECIES OBSERVED : Rodent - rat
DOSE/DURATION : 72 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag,
Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951-
Volume(issue)/page/year: 21,391,1971

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Subcutaneous
SPECIES OBSERVED : Rodent - rat
DOSE/DURATION : 217 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag,
Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951-
Volume(issue)/page/year: 21,391,1971

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Rodent - rat
DOSE/DURATION : 18 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ATXKA8 Archiv fuer Toxikologie. (Berlin, Fed. Rep. Ger.) V.15-31, 1954-74.
For publisher information, see ARTODN. Volume(issue)/page/year: 21,30,1965

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Rodent - mouse
DOSE/DURATION : 275 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
THERAP Therapie. (Doin, Editeurs, 8, Place de l'Odeon, F-75006 Paris,
France) V.1- 1946- Volume(issue)/page/year: 20,67,1965

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intraperitoneal
SPECIES OBSERVED : Rodent - mouse
DOSE/DURATION : 104 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag,
Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951-
Volume(issue)/page/year: 24,166,1974

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Subcutaneous
SPECIES OBSERVED : Rodent - mouse
DOSE/DURATION : 189 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
FRPPAO Farmaco, Edizione Pratica. (Casella Postale 227, 27100 Pavia, Italy)
V.8-43 1953-88 For publisher information, see FRMCE8
Volume(issue)/page/year: 25,519,1970

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Rodent - mouse
DOSE/DURATION : 27 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag,
Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951-
Volume(issue)/page/year: 31,75,1981

TYPE OF TEST : LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Primate - monkey
DOSE/DURATION : 25 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity)
Behavioral - convulsions or effect on seizure threshold
Vascular - BP lowering not characterized in autonomic section
REFERENCE :
IJEBA6 Indian Journal of Experimental Biology. (Publications & Information
Directorate, CSIR, Hillside Rd., New Delhi 110 012, India) V.1- 1963-
Volume(issue)/page/year: 22,539,1984

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Rodent - rabbit
DOSE/DURATION : 14 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag,
Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951-
Volume(issue)/page/year: 18,1435,1968

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intraperitoneal
SPECIES OBSERVED : Rodent - guinea pig
DOSE/DURATION : 85 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
PHARAT Pharmazie. (VEB Verlag Volk und Gesundheit, Neue Gruenstr. 18,
Berlin DDR-1020, Ger. Dem. Rep.) V.1- 1946- Volume(issue)/page/year:
38,749,1983

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Subcutaneous
SPECIES OBSERVED : Rodent - guinea pig
DOSE/DURATION : 190 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans
Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4-
1898- Volume(issue)/page/year: 137,375,1962

TYPE OF TEST : LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Rodent - guinea pig
DOSE/DURATION : 78 mg/kg
TOXIC EFFECTS :
Cardiac - other changes
REFERENCE :
THERAP Therapie. (Doin, Editeurs, 8, Place de l'Odeon, F-75006 Paris,
France) V.1- 1946- Volume(issue)/page/year: 20,67,1965

** OTHER MULTIPLE DOSE TOXICITY DATA **

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Rodent - rat
DOSE/DURATION : 1575 mg/kg/15W-C
TOXIC EFFECTS :
Brain and Coverings - changes in brain weight
Lungs, Thorax, or Respiration - other changes
Biochemical - Metabolism (Intermediary) - other proteins
REFERENCE :
DCTODJ Drug and Chemical Toxicology. (Marcel Dekker, 270 Madison Ave., New
York, NY 10016) V.1- 1977/78- Volume(issue)/page/year: 6,135,1983

** REPRODUCTIVE DATA **

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Rodent - rat
DOSE : 285 mg/kg
SEX/DURATION : female 14 day(s) pre-mating - 21 day(s) post-birth
TOXIC EFFECTS :
Reproductive - Effects on Newborn - behavioral
REFERENCE :
PSYPAG Psychopharmacologia (Berlin). (Berlin, Ger.) V.1-46, 1959-76. For
publisher information, see PSCHDL. Volume(issue)/page/year: 41,237,1975

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Rodent - rat
DOSE : 200 mg/kg
SEX/DURATION : female 7-16 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - pre-implantation mortality (e.g. reduction in
number of implants per female; total number of implants per corpora lutea)
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag,
Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951-
Volume(issue)/page/year: 15,1222,1965

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Rodent - rat
DOSE : 800 mg/kg
SEX/DURATION : female 1-16 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death,
e.g., stunted fetus)
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag,
Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951-
Volume(issue)/page/year: 15,1222,1965

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Rodent - rat
DOSE : 1 gm/kg
SEX/DURATION : female 7-16 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or
resorbed implants per total number of implants)
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag,
Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951-
Volume(issue)/page/year: 15,1222,1965

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Rodent - rat
DOSE : 180 mg/kg
SEX/DURATION : female 14 day(s) pre-mating
female 1-22 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - stillbirth
Reproductive - Effects on Newborn - live birth index (measured after birth)
REFERENCE :
PSYPAG Psychopharmacologia (Berlin). (Berlin, Ger.) V.1-46, 1959-76. For
publisher information, see PSCHDL. Volume(issue)/page/year: 41,237,1975

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Intraperitoneal
SPECIES OBSERVED : Rodent - rat
DOSE : 225 mg/kg
SEX/DURATION : female 23 day(s) pre-mating
female 1-22 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - stillbirth
Reproductive - Effects on Newborn - live birth index (measured after birth)
Reproductive - Effects on Newborn - weaning or lactation index (e.g., #
alive at weaning per # alive at day 4)
REFERENCE :
PSYPAG Psychopharmacologia (Berlin). (Berlin, Ger.) V.1-46, 1959-76. For
publisher information, see PSCHDL. Volume(issue)/page/year: 32,337,1973

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Intraperitoneal
SPECIES OBSERVED : Rodent - rat
DOSE : 210 mg/kg
SEX/DURATION : female 15-21 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - live birth index (measured after birth)
Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight
gain)
REFERENCE :
DPTHDL Developmental Pharmacology and Therapeutics. (S. Karger Pub., Inc.,
79 Fifth Ave., New York, NY 10003) V.1- 1980- Volume(issue)/page/year:
8,17,1985

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Subcutaneous
SPECIES OBSERVED : Rodent - rat
DOSE : 65 mg/kg
SEX/DURATION : female 8-20 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System
Reproductive - Effects on Newborn - biochemical and metabolic
REFERENCE :
TCMUD8 Teratogenesis, Carcinogenesis, and Mutagenesis. (Alan R. Liss, Inc.,
41 E. 11th St., New York, NY 10003) V.1- 1980- Volume(issue)/page/year:
6,173,1986

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Subcutaneous
SPECIES OBSERVED : Rodent - rat
DOSE : 130 mg/kg
SEX/DURATION : female 8-20 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - cardiovascular
(circulatory) system
REFERENCE :
TCMUD8 Teratogenesis, Carcinogenesis, and Mutagenesis. (Alan R. Liss, Inc.,
41 E. 11th St., New York, NY 10003) V.1- 1980- Volume(issue)/page/year:
6,173,1986

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Subcutaneous
SPECIES OBSERVED : Rodent - rat
DOSE : 65 mg/kg
SEX/DURATION : female 8-20 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - biochemical and metabolic
Reproductive - Effects on Newborn - behavioral
REFERENCE :
NRTXDN Neurotoxicology. (Intox Press, Inc., POB 34075, Little Rock, AR
72203) V.1- 1979- Volume(issue)/page/year: 7,365,1986

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Rodent - mouse
DOSE : 9700 mg/kg
SEX/DURATION : female 75 day(s) pre-mating
female 1-22 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - stillbirth
Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4
per # born alive)
Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight
gain)
REFERENCE :
RCOCB8 Research Communications in Chemical Pathology and Pharmacology. (PJD
Pub. Ltd., P.O. Box 966, Westbury, NY 11590) V.1- 1970-
Volume(issue)/page/year: 19,311,1978

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Rodent - mouse
DOSE : 9200 mg/kg
SEX/DURATION : female 10 week(s) pre-mating
female 1-22 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - weaning or lactation index (e.g., #
alive at weaning per # alive at day 4)
REFERENCE :
RCOCB8 Research Communications in Chemical Pathology and Pharmacology. (PJD
Pub. Ltd., P.O. Box 966, Westbury, NY 11590) V.1- 1970-
Volume(issue)/page/year: 19,311,1978

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Subcutaneous
SPECIES OBSERVED : Rodent - mouse
DOSE : 125 mg/kg
SEX/DURATION : female 9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death,
e.g., stunted fetus)
Reproductive - Specific Developmental Abnormalities - Central Nervous System
REFERENCE :
DGDFA5 Development, Growth & Differentiation. (Japan Pub. Trading Co.
(USA), 1255 Howard St., San Francisco, CA 94103) V.11- 1969-
Volume(issue)/page/year: 22,61,1980

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Subcutaneous
SPECIES OBSERVED : Rodent - rabbit
DOSE : 165 mg/kg
SEX/DURATION : female 3-18 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - physical
Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4
per # born alive)
REFERENCE :
APTOA6 Acta Pharmacologica et Toxicologica. (Copenhagen, Denmark) V.1-59,
1945-86. For publisher information, see PHTOEH Volume(issue)/page/year:
20,186,1963

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Intraperitoneal
SPECIES OBSERVED : Rodent - hamster
DOSE : 35 mg/kg
SEX/DURATION : female 8 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System
Reproductive - Specific Developmental Abnormalities - body wall
Reproductive - Specific Developmental Abnormalities - musculoskeletal system
REFERENCE :
RCPBDC Research Communications in Psychology, Psychiatry and Behavior. (PJD
Pub. Ltd., P.O. Box 966, Westbury, NY 11590) V.1- 1976-
Volume(issue)/page/year: 5,275,1980

** MUTATION DATA **

TYPE OF TEST : Specific locus test
ROUTE OF EXPOSURE : Oral
TEST SYSTEM : Insect - Drosophila melanogaster
DOSE/DURATION : 10 mmol/L
REFERENCE :
MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE
Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 260,99,1991

TYPE OF TEST : DNA inhibition
ROUTE OF EXPOSURE : Unreported
TEST SYSTEM : Insect - not otherwise specified
DOSE/DURATION : 10 gm/L
REFERENCE :
JCLBA3 Journal of Cell Biology. (Rockefeller Univ. Press, 1230 York Ave.,
New York, NY 10003) V.12- 1962- Volume(issue)/page/year: 47,182a,1970

TYPE OF TEST : Cytogenetic analysis
ROUTE OF EXPOSURE : Unreported
TEST SYSTEM : Insect - not otherwise specified
DOSE/DURATION : 10 gm/L
REFERENCE :
JCLBA3 Journal of Cell Biology. (Rockefeller Univ. Press, 1230 York Ave.,
New York, NY 10003) V.12- 1962- Volume(issue)/page/year: 47,182a,1970

*** REVIEWS ***

TOXICOLOGY REVIEW
IDPYAK Industrial Pharmacology. (Mount Kisco, NY) V.1-3, 1974-79.
Discontinued. Volume(issue)/page/year: 2,209,1975

*** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA ***

NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA :
NOES - National Occupational Exposure Survey (1983)
NOES Hazard Code - X5236
No. of Facilities: 123 (estimated)
No. of Industries: 1
No. of Occupations: 3
No. of Employees: 2577 (estimated)
No. of Female Employees: 1421 (estimated)

*** STATUS IN U.S. ***

EPA TSCA Section 8(b) CHEMICAL INVENTORY


*** END OF RECORD ***
Search More   
ALL Chemical Property And Toxicity Analysis PAGES IN THIS GROUP
NAMECAS
5H-Dibenz(b,f)azepine,10,11-dihydro-5-(3-morpholinopropionyl)- 18300-60-2
5H-Dibenz(b,f)azepine,10,11-dihydro-5-(3-morpholinopropyl)- 18300-60-2
3,8-Diazabicyclo(3.2.1)octane,3-methyl-8-((2'-nitrothien-5'-yl)vinyl)carbonyl- 57269-49-5
3,7a-Diazacyclohepta(jk)fluoren-7(1H)-one,2,3,3a,4,5,6-hexahydro-10-chloro-3-(phenylmethyl)-,(+-)-, monomethanesulfonate 87255-61-6
5H-Dibenz(b,e)azepine,6,11-dihydro-5-(4-morpholinylacetyl)-,monohydrochloride 70337-07-4
5H-Dibenz(c,e)azepine, 6,7-dihydro-6-phenethyl- 53873-58-8
5H-Dibenz(b,f)azepine,10,11-dihydro-5-(3-(4-piperidino-4-carbamoylpiperidino)propyl)- 5942-95-0
5H-Dibenz(b,f)azepine,10,11-dihydro-5-(2-piperidinoethyl)-,monohydrochloride 5942-95-0
5H-Dibenz(b,f)azepine,10,11-dihydro-5-(m-(piperidinomethyl)benzoyl)-,hydrochloride 5942-95-0
5H-Dibenz(b,f)azepine,10,11-dihydro-5-(o-(piperidinomethyl)benzoyl)-,hydrochloride 5942-95-0
5H-Dibenz(b,f)azepine,10,11-dihydro-5-(p-(piperidinomethyl)benzoyl)-,hydrochloride 5942-95-0
5H-Dibenz(b,f)azepine,10,11-dihydro-5-(3-(4-piperidinopiperidino)propyl)-,dihydrochloride 28028-19-5
5H-Dibenz(b,f)azepine,10,11-dihydro-5-(3-piperidinopropionyl)- 26082-81-5
5H-Dibenz(b,f)azepine,10,11-dihydro-5-(3-piperidinopropyl)- 26082-81-5
3,7a-Diazacyclohepta(jk)fluoren-7(1H)-one,2,3,3a,4,5,6-hexahydro-5,5-dimethyl-3-(phenylmethyl)-, (+-)-, (Z)-2-butenedioate (1:1) 87255-56-9
5H-Dibenz(b,e)azepine,6,11-dihydro-5-(1-piperidinylacetyl)-,monohydrochloride 70337-06-3
5H-Dibenz(b,f)azepine,10,11-dihydro-2-(1-piperidinylmethyl)- 64097-56-9
5H-Dibenz(c,e)azepine, 6,7-dihydro-6-(2-propenyl)-,hydrochloride 65-15-6
5H-Dibenz(c,e)azepine, 6,7-dihydro-6-propyl- 58335-95-8
5H-Dibenz(c,e)azepine, 6,7-dihydro-6-(2-propynyl)-,hydrochloride 51839-51-1
5H-Dibenz(b,e)azepine,6,11-dihydro-5-(1-pyrrolidinylacetyl)-,monohydrochloride 70337-09-6
5H-Dibenz(b,f)azepine,10,11-dihydro-5-(2-(1-pyrrolidinyl)ethyl)-,monohydrochloride 70337-09-6
5H-Dibenz(b,f)azepine,10,11-dihydro-2-(1-pyrrolidinylmethyl)- 64097-59-2
5H-Dibenz(b,f)azepine,10,11-dihydro-5-(m-(1-pyrrolidinylmethyl)benzoyl)-,hydrochloride 64097-59-2
5H-Dibenz(b,f)azepine,10,11-dihydro-5-(o-(1-pyrrolidinylmethyl)benzoyl)-,hydrochloride 64097-59-2
3,7a-Diazacyclohepta(jk)fluoren-7(1H)-one,2,3,3a,4,5,6-hexahydro-6,6-dimethyl-3-(phenylmethyl)-, (+-)-, (Z)-2-butenedioate (1:1) 87255-69-4
5H-Dibenz(b,f)azepine,10,11-dihydro-5-(p-(1-pyrrolidinylmethyl)benzoyl)-,hydrochloride 87255-69-4
5H-Dibenz(b,f)azepine, 10-(2-(dimethylamino)ethyl)- 41972-85-4
5H-Dibenz(b,f)azepine,10-(2-(dimethylamino)ethyl)-5-ethyl- 84142-15-4
5H-Dibenz(b,f)azepine,10-(2-(dimethylamino)ethyl)-8-(ethylsulfonyl)-5-methyl-, hydrochloride 52813-92-0
5H-Dibenz(b,f)azepine,10-(2-(dimethylamino)ethyl)-8-(ethylthio)-5-methyl-,hydrochloride 52813-90-8
5H-Dibenz(b,f)azepine,10-(2-(dimethylamino)ethyl)-5-methyl- 30490-51-8
5H-Dibenz(b,f)azepine, 10-(2-(dimethylamino)ethyl)-,oxalate 101607-50-5
5H-Dibenz(b,f)azepine,5-(2'-(N,N-dimethylamino)-2'-methyl)ethyl- 63918-76-3
5H-Dibenz(b,f)azepine,10-(dimethylaminomethyl)-5-methyl-, hydrochloride 28941-77-7
5H-Dibenz(b,f)azepine,5-(3-(dimethylamino)-2-methylpropyl)-10,11-dihydro- 739-71-9
3,7a-Diazacyclohepta(jk)fluoren-7(1H)-one,2,3,3a,4,5,6-hexahydro-6,6-dimethyl-, (+-)-,(Z)-2-butenedioate (1:1) 87255-66-1
5H-Dibenz(b,f)azepine,5-(3-(dimethylamino)-2-methylpropyl)-10,11-dihydro-,(-)- 3564-75-8
5H-Dibenz(b,f)azepine,5-(3-(dimethylamino)-2-methylpropyl)-10,11-dihydro-,(+)- 3564-66-7
5H-Dibenz(b,f)azepine, 5-(3-(dimethylamino)propyl)- 303-54-8
5H-Dibenz(b,f)azepine,5-(3-(dimethylamino)propyl)-10,11-dihydro- 50-49-7
5H-Dibenz(b,f)azepine,5-(3-(dimethylamino)propyl)-10,11-dihydro-, and3H-1,4- benzodiazepine,7-chloro-2-(methylamino)-5-phenyl-, 4-oxide (2:1) 63918-77-4
5H-Dibenz(b,f)azepine,5-(3-(dimethylamino)propyl)-10,11-dihydro-, and2-((p-chlorobenzyl)(2-(dimethylamino)ethyl)amino)pyridine (1:1) 63918-77-4
5H-Dibenz(b,f)azepine,5-(3-(dimethylamino)propyl)-10,11-dihydro- mixed withethyl alcoholSUBSTANCE DEFINITION :94% 5H-Dibenz(b,f)azepine,5-(3-(dimethylamino)propyl)-10,11-dihydro-:6%ethyl alcoholREFERENCE :AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (HeymansInstitute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4-1898- Volume(issue)/page/year: 148,560,1964 63918-77-4
5H-Dibenz(b,f)azepine,5-(3-(dimethylamino)propyl)-10,11-dihydro-,monohydrochloride 113-52-0
5H-Dibenz(b,f)azepine,5-(3-(dimethylamino)propyl)-10,11-dihydro-, 5-oxide 2207-85-4
5H-Dibenz(b,f)azepine,5-(3-(dimethylamino)propyl)-10,11-dihydro-, 5-oxide,monohydrochloride 19864-71-2
3,7a-Diazacyclohepta(jk)fluoren-7(1H)-one,2,3,3a,4,5,6-hexahydro-5,5-dimethyl-, (+-)-,(Z)-2-butenedioate (1:1) 87255-59-2
5H-Dibenz(b,f)azepine,5-(3-(dimethylamino)propyl)-10,11-dihydro-, mixedwith sodium nitrite (1:4) 87255-59-2
5H-Dibenz(b,f)azepine, 5-(3-(dimethylamino)propyl)-,fumarate 72629-48-2

Free MSDS Search ( Providing 250,000+ Material Properties )
Chemcas.com| Ads link:todaystock.net